US equities |
SPCX $168.43 ▲+5.95% NVDA $237.38 ▲+1.47% MU $1,066.57 ▼-0.77% TSLA $378.73 ▲+2.20% MSFT $525.55 ▲+1.55% SNDK $1,714.69 ▼-0.31% INTC $117.23 ▼-1.76% META $743.33 ▲+2.09%
FinancialContent

Invizyne Technologies Inc. - Common Stock (NQ:IZTC)

16.50 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invizyne Technologies Inc. - Common Stock

News headline image
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
From eXoZymes Inc.
Via GlobeNewswire
News headline image
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 
From Invizyne Technologies, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development 
From Invizyne Technologies, Inc.
Via GlobeNewswire
News headline image
Invizyne Technologies Jumps After IPO ↗
Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00. 
Via Talk Markets
News headline image
Invizyne Technologies Announces Closing of Initial Public Offering
From Invizyne Technologies, Inc.
Via GlobeNewswire
News headline image
Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology 
From Invizyne Technologies, Inc.
Via GlobeNewswire